Figure 3From: Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approachesReproducibility of SELDI ToF mass spectra. Different relative intensities of peptide peaks between glioblastoma diagnosed (n = 35) and control group (n = 30); (A) down-regulated peptide with m/z 2948.04 in glioblastoma patients. (B) down-regulated peptide with and 6440.01 in glioblastoma patients.Back to article page